EMA Authorised: Abiraterone Krka (abiraterone acetate) — Krka, d.d., Novo mesto

View source ↗

Summary

EMA authorised Abiraterone Krka (abiraterone acetate) for prostatic neoplasms (prostate cancer); decision date 18 December 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone Krka (abiraterone acetate)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Krka, d.d., Novo mesto. Decision date: 18/12/2025